Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Mangiacavalli S, Cartia CS, Galli M, Pezzatti S, Belotti A, Fazio F, Mina R, Marcatti M, Cafro A, Zambello R, Paris L, Barilà G, Olivares C, Pompa A, Mazza R, Farina F, Soldarini M, Benvenuti P, Pagani G, Palumbo M, Masoni V, Ferretti VV, Klersy C, Arcaini L, Petrucci MT. Mangiacavalli S, et al. Among authors: marcatti m. Haematologica. 2023 Mar 1;108(3):833-842. doi: 10.3324/haematol.2022.281342. Haematologica. 2023. PMID: 36200419 Free PMC article.
Iron increases the susceptibility of multiple myeloma cells to bortezomib.
Campanella A, Santambrogio P, Fontana F, Frenquelli M, Cenci S, Marcatti M, Sitia R, Tonon G, Camaschella C. Campanella A, et al. Among authors: marcatti m. Haematologica. 2013 Jun;98(6):971-9. doi: 10.3324/haematol.2012.074872. Epub 2012 Dec 14. Haematologica. 2013. PMID: 23242599 Free PMC article.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Larocca A, et al. Among authors: marcatti m. Blood. 2013 Oct 17;122(16):2799-806. doi: 10.1182/blood-2013-03-488676. Epub 2013 Aug 16. Blood. 2013. PMID: 23954889 Free article. Clinical Trial.
Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Palumbo A, et al. Among authors: marcatti m. N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888. N Engl J Med. 2014. PMID: 25184862 Free article. Clinical Trial.
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.
Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F. Cerrato C, et al. Among authors: marcatti m. J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19. J Cancer Res Clin Oncol. 2018. PMID: 29675792 Free article. Clinical Trial.
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F. D'Agostino M, et al. Among authors: marcatti m. Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14. Crit Rev Oncol Hematol. 2018. PMID: 30447931 Free article. Review.
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Montefusco V, Corso A, Galli M, Ardoino I, Pezzatti S, Carniti C, Patriarca F, Gherlinzoni F, Zambello R, Sammassimo S, Marcatti M, Nozza A, Crippa C, Cafro AM, Baldini L, Corradini P. Montefusco V, et al. Among authors: marcatti m. Br J Haematol. 2020 Mar;188(6):907-917. doi: 10.1111/bjh.16287. Epub 2020 Jan 2. Br J Haematol. 2020. PMID: 31898319 Free article.
Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients.
Serpenti F, Lorentino F, Marktel S, Milani R, Messina C, Greco R, Girlanda S, Clerici D, Giglio F, Liberatore C, Farina F, Mastaglio S, Piemontese S, Guggiari E, Lunghi F, Marcatti M, Carrabba MG, Bernardi M, Bonini C, Assanelli A, Corti C, Peccatori J, Ciceri F, Lupo-Stanghellini MT. Serpenti F, et al. Among authors: marcatti m. Front Oncol. 2021 Jul 22;11:705568. doi: 10.3389/fonc.2021.705568. eCollection 2021. Front Oncol. 2021. PMID: 34367991 Free PMC article.
82 results